DPH2: A Promising Drug Target / Biomarker (G1802)

Target Name: DPH2

NCBI ID: G1802

DPH2

DPH2: A Promising Drug Target / Biomarker

Drug-resistant bacterial infections are a major public health concern, resulting in significant morbidity and economic burden. One of the major factors contributing to the development of drug-resistant infections is the overuse and misuse of antibiotics. Antibiotics are often used to treat bacterial infections, but they can have harmful effects on the gut microbiota, leading to the development of antibiotic-resistant strains. To combat this problem, there is a need for new and effective approaches to treat bacterial infections.

DPH2: A Potential Drug Target and Biomarker

DPH2 (Dihydroxyproline) is a protein that is synthesized in the gut and has been shown to play a role in the development of antibiotic-resistant bacterial infections. It is a key regulator of bacterial growth and has been shown to affect the expression of genes involved in bacterial stress responses, such as the production of toxins and the regulation of bacterial cell wall biosynthesis.

DPH2 has also been shown to play a role in the development of antibiotic-resistant bacterial infections in animal models. Studies have shown that DPH2-deficient bacteria are more susceptible to various bacterial infections, including antibiotic-resistant strains. Additionally, DPH2 has been shown to be involved in the regulation of bacterial cell wall biosynthesis, which is a critical factor in the development of antibiotic-resistant bacterial infections.

DPH2 as a Potential Drug Target

The development of antibiotic-resistant bacterial infections is a major public health concern, and there is a need for new and effective approaches to treat these infections. DPH2 has been shown to be involved in the development of antibiotic-resistant bacterial infections, making it a potential drug target.

One way to target DPH2 is through the inhibition of its activity as a transcriptional regulator. This can be done through the use of small molecules or antibodies that bind to DPH2 and prevent it from binding to its target genes. Additionally, drugs that inhibit the activity of DPH2 can be used to treat antibiotic-resistant bacterial infections.

DPH2 as a Biomarker

DPH2 has also been shown to be a potential biomarker for the development of antibiotic-resistant bacterial infections. This is because its levels are often affected by the expression of genes involved in the development of antibiotic-resistant bacterial infections. Therefore, the levels of DPH2 can be used as an indicator of the level of bacterial stress caused by antibiotic exposure.

DPH2 has been shown to be involved in the regulation of bacterial cell wall biosynthesis, which is a critical factor in the development of antibiotic-resistant bacterial infections. Therefore, the levels of DPH2 can be used as a biomarker for the development of antibiotic-resistant bacterial infections. This can be done through the use of antibodies that bind to DPH2 and measure its levels in the gut.

Conclusion

DPH2 is a protein that is involved in the development of antibiotic-resistant bacterial infections. It has been shown to play a role in the regulation of bacterial cell wall biosynthesis and has been shown to contribute to the development of antibiotic-resistant bacterial infections in animal models.

The development of antibiotic-resistant bacterial infections is a major public health concern, and there is a need for new and effective approaches to treat these infections. The inhibition of DPH2 activity or the measurement of its levels in the gut may be a promising way to treat antibiotic-resistant bacterial infections. Further research is needed to determine the effectiveness of these approaches and to develop new treatments for antibiotic-resistant bacterial infections.

Protein Name: Diphthamide Biosynthesis 2

Functions: Required for the first step of diphthamide biosynthesis, a post-translational modification of histidine which occurs in elongation factor 2 (PubMed:32576952). DPH1 and DPH2 transfer a 3-amino-3-carboxypropyl (ACP) group from S-adenosyl-L-methionine (SAM) to a histidine residue, the reaction is assisted by a reduction system comprising DPH3 and a NADH-dependent reductase (By similarity). Facilitates the reduction of the catalytic iron-sulfur cluster found in the DPH1 subunit (By similarity)

The "DPH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets